Company Overview of Tocagen Inc.
Tocagen Inc., a biopharmaceutical company, discovers, develops, and commercializes products for the treatment of cancer. The company focuses on developing a treatment for High Grade Glioma, a type of brain cancer that includes glioblastoma multiforme and anaplastic astrocytomas. Its products include Toca 511 and Toca FC that allows selective targeting of cancer cells, as well as a selective, local, and systemic antitumor immune response without off-target toxicity; and Toca Gamma that leverages the immune system to clear locally injected cancerous tumors, as well as to create an arsenal of targeted immune cells to kill more distant metastatic cancer cells. The company was founded in 2007 and...
3030 Bunker Hill Street
San Diego, CA 92109
Founded in 2007
Key Executives for Tocagen Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Executive Vice President of Research & Pharmaceutical Development
Co-Founder, Executive Vice President of Corporate Development and Director
Chief Financial Officer, Executive Vice President and Director
Head of Business Development and Product Manager
Compensation as of Fiscal Year 2016.
Tocagen Inc. Key Developments
Tocagen Inc. Announces First Patient Enrolled in Toca 6
Sep 22 16
Tocagen Inc. announced the first patient has been enrolled in Toca 6, a Phase 1b study evaluating intravenously delivered Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release 5-fluorocytosine) in patients with metastatic cancers. The study is planned to include patients with colorectal cancer with liver metastases; metastatic renal cell carcinoma; locally advanced or metastatic pancreatic cancer or breast cancer; brain metastases from non-small cell lung cancer or breast cancers; and locally advanced or recurrent melanoma. The trial will evaluate if Toca 511-delivered genes and resulting proteins are detected in tumor samples, following intravenous administration of Toca 511. Safety, tumor response and survival results will also be assessed. In this first patient, who has metastatic colorectal cancer, intravenous Toca 511 and oral Toca FC was well tolerated. Toca 511 viral genes and cytosine deaminase (CD) were present in tumor samples. Additional results from this trial will be presented at a future scientific conference.
RiboMed and Tocagen Collaborate to Analyze Epigenetic Prognostic Markers, Including MGMT, in Recurrent Brain Tumors
Jul 6 16
RiboMed Biotechnologies, Inc. and Tocagen Inc. announced a collaboration to analyze potential epigenetic prognostic and predictive markers, including the gene for the DNA repair enzyme O-6-Methylguanine-DNA Methyltransferase (MGMT), in Tocagen's clinical trials evaluating the investigational treatment Toca 511 & Toca FC in patients with recurrent high grade gliomas (HGGs). HGGs, including glioblastoma, are the most aggressive primary malignant brain tumors and are treated initially with surgery, radiation and chemotherapy, including temozolomide (TMZ, Temodar®). Response to TMZ treatment is variable and almost all tumors ultimately recur. Tumor sensitivity to TMZ correlates with the inactivation of MGMT and longer overall survival in patients with glioblastoma. Inactivation of MGMT is primarily caused by DNA methylation in the MGMT gene's control region. The collaborative research also includes evaluation of RiboMed's GliomaSTRAT assay initially in tumor samples from earlier clinical trials. GliomaSTRAT is designed to stratify gliomas by both tumor aggressiveness and potential for drug activity. In addition to MGMT methylation, GliomaSTRAT includes a DNA methylation biomarker panel to determine the tumor's CpG Island Methylator Phenotype (CIMP) and detection of the IDH1 R132H mutation known to cause CIMP. These prognostic biomarkers identify two distinct tumor subtypes that show significant differences in overall survival, independent of initial tumor grade classification.
Tocagen Inc. Presents at 2016 BIO International Convention, Jun-06-2016 through Jun-09-2016
May 26 16
Tocagen Inc. Presents at 2016 BIO International Convention, Jun-06-2016 through Jun-09-2016. Venue: Moscone Center, San Francisco, California, United States. Presentation Date & Speakers: Jun-08-2016. Jun-09-2016, Asha Das, Vice President of Clinical Development and Medical Affairs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|